Swedish Orphan Biovitrum (SOBI) has agreed to acquire Arthrosi Therapeutics Inc., a late-stage biotechnology company developing a highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, for up to $1.5 billion in total transaction value, including an upfront payment at closing of $950 million, subject to customary adjustments, and contingent consideration of up to $550 million. The transaction...